Gilead invests $21.25M in HOOKIPA for 15M shares at $1.4167 each

HOOKIPA Pharma Inc.

Gilead purchased 15M shares for ~$21.25M at $1.4167/share; now holds 19.4% of HOOK outstanding stock.
HOOKIPA may sell up to $8.75M additional shares to Gilead in future equity raises under same agreement.
Funds to advance HIV therapeutic vaccine HB-500 through Phase 1; trial expected to start H1 2024.
Agreement replaces 2022 stock purchase agreement; total committed $30M now largely funded.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

HOOKIPA Pharma Inc. amended Amended and Restated Stock Purchase Agreement with Gilead Sciences, Inc. valued at approximately $21.25 million (effective 2023-12-20).

Action: amendment
Agreement: equity purchase
Counterparty: Gilead Sciences, Inc.
Value: approximately $21.25 million
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, (the “Effective Date”), HOOKIPA Pharma Inc. (the “Company”) entered into an Amended and Restated Stock Purchase Agreement (the “A&R Stock Purchase Agreement”) with Gilead Sciences, Inc. (“Gilead”), which amends and restates in its entirety the Company’s Stock Purchase Agreement, dated February 15, 2022, with Gilead, pursuant to which Gilead had purchased $5.0 million of the Company’s Common Stock and committed to purchase an additional $30.0 million.

View on SEC.gov

Browse all material agreements →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-127949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.